{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/mastitis-breast-abscess/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"6882319d-cec4-58ac-a5fb-bfad5a8c44b5","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 4dc029be-db05-4376-9665-a78200c543ce --><h2>Metronidazole</h2><!-- end field 4dc029be-db05-4376-9665-a78200c543ce -->","summary":"","htmlStringContent":"<!-- begin item c519103d-89a0-454a-aada-a78200c53b9d --><!-- end item c519103d-89a0-454a-aada-a78200c53b9d -->","topic":{"id":"612445a9-31b6-5130-bb99-4389c0f9c4af","topicId":"8dd98aac-dd7a-4981-bb01-5e666b4686b6","topicName":"Mastitis and breast abscess","slug":"mastitis-breast-abscess","lastRevised":"January 2021","chapters":[{"id":"d054cbf1-e596-5afd-8a75-f3d051c621dc","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"de83cb42-8301-5164-81a9-f0c4ab5a83c2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"610b1eb8-dd62-5e7e-b3bf-deb28c7072aa","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"c44cbf7c-02c4-5674-abb6-1c6be6131e3b","slug":"changes","fullItemName":"Changes"},{"id":"9d333c13-3643-5811-9a29-a919983994aa","slug":"update","fullItemName":"Update"}]},{"id":"f993c606-c828-51da-a43a-6029a7e07f40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a4f11480-406f-5573-9e6b-b2747a513a11","slug":"goals","fullItemName":"Goals"},{"id":"5020b6cc-9441-50c0-b8dd-94fcf8bdf761","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"948e09e3-ff32-5344-a06f-e0a9331eff4f","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e253dff2-3341-5c3a-8c2c-a8c5c9d27491","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7a7fe239-eefb-5a7a-936c-c1c01d919b6e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"844a01a3-e6d9-5962-905c-52aaa284973a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"13965c3c-cc8a-575f-8e2d-056c9590196a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"edd589e4-be3e-52d6-b1ea-c2095f08f38e","slug":"definition","fullItemName":"Definition"},{"id":"06b05f0c-3f18-5d1a-994a-02d388348b53","slug":"causes","fullItemName":"Causes"},{"id":"ac2b0ec4-d2dd-5b82-999f-aa4fb681433e","slug":"predisposing-factors","fullItemName":"Predisposing factors"},{"id":"033ddd74-dfdc-5a2d-bb82-453baebee36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9ccd068b-aec1-59bb-a0dc-497e330227b3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"bf45f222-3e69-50c6-b73f-cd089ff22c65","slug":"complications","fullItemName":"Complications"}]},{"id":"1facde51-ce1f-55fa-889f-f079ac8b1283","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4d19871b-504c-5d1d-8e27-298e0a8e40b2","slug":"when-to-suspect-mastitis","fullItemName":"When to suspect mastitis"},{"id":"1a7eb0d1-33d6-539d-bfc3-0b12f1ec6451","slug":"when-to-suspect-a-breast-abscess","fullItemName":"When to suspect a breast abscess"},{"id":"3478864a-a09e-5e3f-ab1e-bd6dc34d0ae1","slug":"investigations","fullItemName":"Investigations"},{"id":"f70b7f79-5c5c-5a9d-a586-dad7ec33698c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1bdc74c8-e4f7-574c-a93a-ea9103718273","fullItemName":"Management","slug":"management","subChapters":[{"id":"7d9d079a-de35-5f76-8cfe-4303cce22c3e","slug":"management-lactating-women","fullItemName":"Scenario: Management - lactating women"},{"id":"95e2db4c-1f7a-5dfe-b04b-5edb440448bd","slug":"management-non-lactating-women","fullItemName":"Scenario: Management - non-lactating women"},{"id":"d1bd1c0d-5efe-5925-92a2-57663e0af1d5","slug":"management-breast-abscess","fullItemName":"Scenario: Management - breast abscess"}]},{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"02c4d465-606a-5a45-bb76-7884e6655d29","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"35a080bd-68dc-5e30-8e45-c15b80ad6691","slug":"erythromycin-claithromycin","fullItemName":"Erythromycin and claithromycin"},{"id":"3354cafa-cf61-54b5-8be9-14286cac7d43","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"6882319d-cec4-58ac-a5fb-bfad5a8c44b5","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"5ca61020-4e7e-58c8-89de-963d0f9fad55","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"cdcf64dc-7d30-54dc-a4b3-c2cbb2e11318","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"9ed2bf1e-0ab0-5318-ab26-7125ea334bc2","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a07ffae7-9042-5683-b005-a39cb64cfe07","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3647fb21-13e1-5087-8638-500053de452d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d3f0e67e-27f7-5dab-bf77-6fd2fb6c04aa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c1eba960-eb26-5c75-a69c-d1b75d6bb18b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e3453acf-65bd-5b33-854f-a6e08be6d75c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d2222456-9dbf-5408-9e2a-d06f803d315e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"380f683a-7c81-5b75-951f-0131a6c03266","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 733b0562-632a-4946-bf99-a78200c6f83a --><h3>Contraindications and cautions</h3><!-- end field 733b0562-632a-4946-bf99-a78200c6f83a -->","summary":"","htmlStringContent":"<!-- begin item e4101b1d-8787-419f-92f5-a78200c6f639 --><!-- begin field 423d90d0-f523-47dc-b351-a78200c6f83a --><ul><li><strong>Do not prescribe metronidazole to a person with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li><li>Cockayne syndrome. Cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories). For people with Cockayne syndrome specialist advice should therefore be sought before prescribing metronidazole. </li></ul></li><li><strong>Prescribe oral metronidazole with caution:</strong><ul><li>In people with active or chronic severe peripheral and central nervous system disease (due to the risk of neurological aggravation).</li><li>In people with severe liver disease and hepatic encephalopathy (due to substantial impairment of metronidazole clearance) — the daily dose should be reduced to one-third and may be administered once daily.</li><li>For prolonged use (longer than 10 days) — may be associated with peripheral neuropathy or leucopenia, although both effects are usually reversible.<ul><li>The manufacturer recommends that a full blood count should be carried out regularly in a person taking metronidazole for longer than 10 days, and the person should be monitored for adverse reactions, such as peripheral or central neuropathy (including paraesthesia, ataxia, dizziness, or seizures).</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field 423d90d0-f523-47dc-b351-a78200c6f83a --><!-- end item e4101b1d-8787-419f-92f5-a78200c6f639 -->","subChapters":[]},{"id":"0fe159af-7f32-5263-92a5-e46c3d9e7ad2","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field a740b00c-ba48-428c-9c8e-a78200c70a37 --><h3>Adverse effects</h3><!-- end field a740b00c-ba48-428c-9c8e-a78200c70a37 -->","summary":"","htmlStringContent":"<!-- begin item 4d5572c2-6414-45a4-b9ff-a78200c70861 --><!-- begin field 33b472f0-025f-4025-bfca-a78200c70a37 --><ul><li><strong>Gastrointestinal disturbances (including nausea and vomiting), taste disturbances, furred tongue, oral mucositis, and anorexia</strong> are possible adverse effects of metronidazole.<ul><li>Very rarely, hepatitis, jaundice, pancreatitis, drowsiness, dizziness, headache, ataxia, psychotic disorders, darkening of urine, thrombocytopenia, pancytopenia, myalgia, arthralgia, visual disturbances, rash, pruritis, and erythema multiforme have been reported.</li></ul></li><li><strong>Advise the person not to drive or operate machinery if </strong>drowsiness, dizziness, confusion, hallucinations, convulsions, or transient visual disturbances occur.</li><li>Severe bullous skin reactions such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) or acute generalized exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field 33b472f0-025f-4025-bfca-a78200c70a37 --><!-- end item 4d5572c2-6414-45a4-b9ff-a78200c70861 -->","subChapters":[]},{"id":"1492513f-2966-5f85-b3eb-6ea2315915d7","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ef52f993-cbdc-49cf-9b93-a78200c717cb --><h3>Drug interactions</h3><!-- end field ef52f993-cbdc-49cf-9b93-a78200c717cb -->","summary":"","htmlStringContent":"<!-- begin item 7bdc97dd-a4c2-46c4-9cc6-a78200c715a8 --><!-- begin field cae50359-d8ba-482b-b6bd-a78200c717cb --><ul><li><strong>Key drug interactions associated with oral metronidazole include:</strong><ul><li><strong>Alcohol </strong>— some people taking oral metronidazole experience a disulfiram-like reaction (flushing, increased respiratory rate, increased pulse rate, nausea, headache, and dizziness) with alcohol.<ul><li>Although there is no conclusive evidence to support this interaction, warn the person that they <em>might</em> experience this reaction if they drink alcohol whilst taking metronidazole. Alcohol should be avoided during treatment with metronidazole and for at least 48 hours afterwards.</li></ul></li><li><strong>Anticoagulants </strong>— the anticoagulant effects of warfarin can be markedly increased by metronidazole.<ul><li>Monitor the international normalized ratio (INR) if metronidazole is given with warfarin and adjust the warfarin dose accordingly.</li><li>Warn the person of the possible risk of increased bruising and bleeding and advise them on when to seek medical help.</li></ul></li><li><strong>Ciclosporin </strong>— people receiving ciclosporin are at risk of elevated serum ciclosporin levels.<ul><li>When co-administration of metronidazole and ciclosporin are necessary, serum ciclosporin and creatinine levels should be closely monitored.</li></ul></li><li><strong>Lithium </strong>— raised lithium levels accompanied by evidence of possible renal damage has been reported in people treated simultaneously with lithium and metronidazole.<ul><li>Before starting metronidazole in a person taking lithium, seek specialist advice about tapering or stopping lithium treatment. If concurrent treatment is unavoidable, plasma concentrations of lithium, creatinine, and electrolytes should be monitored closely.</li></ul></li></ul></li><li><strong>Contraceptives </strong>— additional contraceptive precautions are <em>not</em> required during or after courses of metronidazole.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">FSRH, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">Preston, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/mastitis-breast-abscess/references/\">BNF, 2021</a>]</p><!-- end field cae50359-d8ba-482b-b6bd-a78200c717cb --><!-- end item 7bdc97dd-a4c2-46c4-9cc6-a78200c715a8 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}